Ameritas Advisory Services’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
Ameritas Advisory Services's CRSP Position: Q3 2026 in Review
Ameritas Advisory Services reduced its CRISPR Therapeutics (CRSP) stake by 15% in Q3 2026, selling an estimated $7.99K and leaving 870 shares worth $48.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1276.
Ameritas Advisory Services first reported a position in CRSP in Q1 2021 and has held it in 6 quarters since. The position peaked at $55.5K in Q2 2026. 503 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- Ameritas Advisory Services held 870 shares of CRISPR Therapeutics worth $48.1K as of Q3 2026.
- Ameritas Advisory Services sold 148 CRISPR Therapeutics shares in Q3 2026, an estimated $7.99K.
- CRISPR Therapeutics made up ﹤0.01% of Ameritas Advisory Services's portfolio in Q3 2026, its #1276 holding.
- Ameritas Advisory Services first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 6 quarters since.
- Ameritas Advisory Services's CRISPR Therapeutics position peaked at $55.5K in Q2 2026.
- 503 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on Ameritas Advisory Services's 13F filing for Q3 2026, filed 12 Nov 2026.